Clinical trial NCT02362724: Evaluation of Investigational (Frequent Replacement) FRP Lens for Daily Wear
Official title: Evaluation of the CooperVision, Inc. Sapphire and Pearl Silicone Hydrogel Daily Wear Contact Lenses When Used for Frequent Replacement for Up to One (1) Month of Daily Wear.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ametropia
Lead sponsor: CooperVision International Limited (CVIL)
Sponsor class: INDUSTRY
First posted: 2015-02-13
Enrollment: 89
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to compare the investigational contact lens to a marketed contact lens.

The study results were not used for design validation of investigational contact lens,

Detailed description: The objective of this evaluation is to provide evidence supporting the claim that the performance of the Test Lens is substantially equivalent to that of the Control Lens when used in a one month (up to 30 days) recommended replacement, daily wear modality.

The study results were not used for design validation of investigational contact lens,

Eligibility criteria: Inclusion Criteria:

* Prior to being considered eligible to participate in this study, each subject MUST:

  1. Be at least 18 years of age as of the date of evaluation for the study.
  2. Have:

     1. Read the Informed Consent
     2. been given an explanation of the Informed Consent
     3. indicated understanding of the Informed Consent
     4. signed the Informed Consent document.
  3. Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
  4. Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses at least 5 days per week for at least 8 hours per day for at least one month prior to participation in the study.
  5. Possess or obtain prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.
  6. Be in good general health, based on his/her knowledge.
  7. Require spectacle lens powers between -0.50 and -8.00 diopters sphere with no more than 1.50 diopter of refractive astigmatism and be willing to wear contact lenses in both eyes.
  8. Have manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 in each eye.
  9. To be eligible for lens dispensing, the subject must achieve 20/30 VA or better in each eye with the study lens and the investigator must judge the fit as acceptable or optimal.

Exclusion Criteria:

* Subjects may not be enrolled in this study if any of the following apply: The subject is currently or has:

  1. Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes for the duration of the study. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis.
  2. Poor personal hygiene.
  3. Any active participation in another clinical trial during this trial or within 30 days prior to this study.
  4. To the best of the subject's knowledge, she is currently pregnant, is lactating or is planning a pregnancy within the next 3 months.
  5. A member, relative or household member of the investigator or of the investigational office staff.
  6. Has a known sensitivity to the ingredients used in the MPS approved for use in the study and is unable or unwilling to use the alternate care system.
  7. Previous refractive surgery; or current or previous orthokeratology treatment.
  8. Is aphakic or psuedophakic.
  9. Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, scleroderma, keratoconus or uncontrolled diabetes.
  10. The need for topical ocular medications or any systemic medication which might interfere with contact lens wear or require the lenses to be removed during the day.
  11. The presence of clinically significant (grade 2, 3 or 4) anterior segment abnormalities; or the presence of any inflammations such as iritis; or any infection of the eye, lids, or associated structures.
  12. A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, iritis, bacterial or fungal infections.
  13. A history of papillary conjunctivitis that has interfered with contact lens wear.
  14. Slit lamp findings that would contraindicate contact lens wear, including but not limited to:

      * Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining \> Grade 2
      * Pterygium
      * Corneal scars within the visual axis
      * Neovascularization or ghost vessels \> 1.0 mm in from the limbus
      * Giant papillary conjunctivitis (GPC) of \> Grade 2
      * Anterior uveitis or iritis
      * Seborrheic eczema, seborrheic conjunctivitis or blepharitis

Primary outcomes:
measure: Slit Lamp Findings for Epithelial Edema
timeFrame: Baseline (After lens dispensing)
measure: Slit Lamp Findings for Epithelial Edema
timeFrame: 1 Month
measure: Slit Lamp Findings for Stromal Edema
timeFrame: Baseline (After lens dispensing)
measure: Slit Lamp Findings for Stromal Edema
timeFrame: 1 month
measure: Slit Lamp Findings for Corneal Infiltrates
timeFrame: Baseline (After lens dispensing)
measure: Slit Lamp Findings for Corneal Infiltrates
timeFrame: 1 Month
measure: Slit Lamp Findings for Corneal Vascularization
timeFrame: Baseline (After lens dispensing)
measure: Slit Lamp Findings for Corneal Vascularization
timeFrame: 1 month
measure: Slit Lamp Findings for Limbal Hyperemia
timeFrame: Baseline (After lens dispensing)
measure: Slit Lamp Findings for Limbal Hyperemia
timeFrame: 1 month
measure: Slit Lamp Findings for Bulbar Hyperemia
timeFrame: Baseline (After lens dispensing)
measure: Slit Lamp Findings for Bulbar Hyperemia
timeFrame: 1 month
measure: Slit Lamp Findings for Palpebral Conjunctiva
timeFrame: Baseline (After lens dispensing)
measure: Slit Lamp Findings for Palpebral Conjunctiva
timeFrame: 1 month
measure: Slit Lamp Findings for Other Findings
timeFrame: Baseline (After lens dispensing)
measure: Slit Lamp Findings for Other Findings
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Eric M White OD, Inc.
state: California
city: Torrance
country: United States
facility: Office of Mark E Nakano, O.D.
state: California
city: Denver
country: United States
facility: Advanced Family Eye Care
state: North Carolina
city: Athens
country: United States
facility: Quinn Foster & Associates
state: Ohio
city: Brentwood
country: United States
facility: Primary Eyecare Group, P.C.
state: Tennessee
city: Amarillo
country: United States
facility: Premier Vision Services, LLC
state: Texas
Study officials:
affiliation: Sterling IRB
name: Steven L Saltzman, MD, FACOG
role: STUDY_CHAIR
References: